News

Public · Published

BillionToOne Q3 revenue rises 47%, raises 2026 outlook

BillionToOne reported third-quarter revenue growth of 47% year over year, driven by higher test volumes and prices. Net income and diluted earnings per share also increased sharply from a year earlier. It raised its 2026 revenue outlook to the headline's stated range and expects current profitability despite continued investment.

Published:

Updated:

What happened

BillionToOne reported third-quarter revenue growth of 47% year over year, driven by higher test volumes and prices. Net income and diluted earnings per share also increased sharply from a year earlier. It raised its 2026 revenue outlook to the headline’s stated range and expects current profitability despite continued investment.

Confirmed

Global impact / market context

Higher test volume and selling prices both contributed to revenue growth, while near-doubling oncology testing revenue points to a growing business line. If those drivers continue, they could support sales and help fund investment; maintaining profitability would indicate the company is balancing growth spending with costs.

Analyst inference

The company’s raised outlook gives investors a higher stated revenue range for 2026, but the article provides no share-price reaction to the results. It also reports a $125 median analyst price target and a $110.45 November 3 closing price, figures that describe expectations rather than assured returns.

Confirmed

What to watch

  1. Watch whether test volumes and average selling prices keep rising; the company attributed Q3 revenue growth to more tests delivered and a higher average price per test. Analyst inference
  2. Track progress against the raised 2026 revenue outlook and whether the company maintains current profitability while continuing investment, as it expects. Analyst inference
  3. Check whether oncology clinical testing revenue continues expanding after nearly doubling, and whether that segment’s growth contributes to continued overall revenue gains. Analyst inference

Evidence

  • Original source link unavailable